Elicio Therapeutics Stock Analysis
| ELTX Stock | 8.23 0.01 0.12% |
Elicio Therapeutics is fairly valued with Real Value of 8.1 and Target Price of 9.5. The main objective of Elicio Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Elicio Therapeutics is worth, separate from its market price. There are two main types of Elicio Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Elicio Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Elicio Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Elicio Stock trading window is adjusted to America/New York timezone.
Elicio |
Elicio Stock Analysis Notes
About 29.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.44. Elicio Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2023. To learn more about Elicio Therapeutics call Robert Connelly at 857 209 0050 or check out https://elicio.com.Elicio Therapeutics Investment Alerts
| Elicio Therapeutics is way too risky over 90 days horizon | |
| Elicio Therapeutics appears to be risky and price may revert if volatility continues | |
| Elicio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (35.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elicio Therapeutics generates negative cash flow from operations | |
| About 29.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Peter DeMuth of 44400 shares of Elicio Therapeutics at 8.92 subject to Rule 16b-3 |
Elicio Therapeutics Upcoming and Recent Events
Earnings reports are used by Elicio Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Elicio Largest EPS Surprises
Earnings surprises can significantly impact Elicio Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.96 | -0.64 | 0.32 | 33 | ||
2022-05-17 | 2022-03-31 | -4.35 | -4.8 | -0.45 | 10 | ||
2023-11-09 | 2023-09-30 | -0.8 | -1.27 | -0.47 | 58 |
Elicio Therapeutics Environmental, Social, and Governance (ESG) Scores
Elicio Therapeutics' ESG score is a quantitative measure that evaluates Elicio Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Elicio Therapeutics' operations that may have significant financial implications and affect Elicio Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Elicio Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.2 M.Elicio Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.49) | (1.57) | |
| Return On Capital Employed | (1.85) | (1.76) | |
| Return On Assets | (1.49) | (1.57) | |
| Return On Equity | (3.56) | (3.38) |
Management Efficiency
Elicio Therapeutics has return on total asset (ROA) of (0.737) % which means that it has lost $0.737 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.5302) %, meaning that it created substantial loss on money invested by shareholders. Elicio Therapeutics' management efficiency ratios could be used to measure how well Elicio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.57 in 2025. Return On Capital Employed is likely to rise to -1.76 in 2025. At this time, Elicio Therapeutics' Other Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 4.2 M in 2025, whereas Total Assets are likely to drop slightly above 20.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.59 | 2.46 | |
| Tangible Book Value Per Share | 2.59 | 2.46 | |
| Enterprise Value Over EBITDA | (1.26) | (1.20) | |
| Price Book Value Ratio | 3.34 | 3.50 | |
| Enterprise Value Multiple | (1.26) | (1.20) | |
| Price Fair Value | 3.34 | 3.50 | |
| Enterprise Value | 32.6 M | 34.2 M |
Understanding the operational decisions made by Elicio Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 26th of February, Elicio Therapeutics shows the Coefficient Of Variation of 626.6, downside deviation of 3.98, and Mean Deviation of 3.75. Elicio Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Elicio Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Elicio Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Elicio Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Elicio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elicio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elicio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elicio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Elicio Therapeutics Outstanding Bonds
Elicio Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Elicio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Elicio bonds can be classified according to their maturity, which is the date when Elicio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Elicio Therapeutics Predictive Daily Indicators
Elicio Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Elicio Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Elicio Therapeutics Corporate Filings
| 5th of February 2025 Other Reports | ViewVerify | |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 30th of January 2025 Other Reports | ViewVerify | |
8K | 23rd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 22nd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of January 2025 Other Reports | ViewVerify | |
| 2nd of January 2025 Other Reports | ViewVerify | |
F4 | 18th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Elicio Therapeutics Forecast Models
Elicio Therapeutics' time-series forecasting models are one of many Elicio Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Elicio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Elicio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Elicio Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Elicio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Elicio Therapeutics. By using and applying Elicio Stock analysis, traders can create a robust methodology for identifying Elicio entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.07) | (1.13) | |
| Operating Profit Margin | (1.03) | (1.09) | |
| Net Loss | (1.07) | (1.13) | |
| Gross Profit Margin | 0.86 | 0.46 |
Current Elicio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Elicio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Elicio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 9.5 | Buy | 3 | Odds |
Most Elicio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Elicio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Elicio Therapeutics, talking to its executives and customers, or listening to Elicio conference calls.
Elicio Stock Analysis Indicators
Elicio Therapeutics stock analysis indicators help investors evaluate how Elicio Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Elicio Therapeutics shares will generate the highest return on investment. By understating and applying Elicio Therapeutics stock analysis, traders can identify Elicio Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 8.4 M | |
| Common Stock Shares Outstanding | 5.1 M | |
| Total Stockholder Equity | 11.4 M | |
| Property Plant And Equipment Net | 7.3 M | |
| Cash And Short Term Investments | 12.9 M | |
| Cash | 12.9 M | |
| Accounts Payable | 4.4 M | |
| Net Debt | -6 M | |
| 50 Day M A | 6.8437 | |
| Total Current Liabilities | 9.8 M | |
| Other Operating Expenses | 35.7 M | |
| Non Current Assets Total | 10.8 M | |
| Non Currrent Assets Other | 2.8 M | |
| Stock Based Compensation | 1.2 M |
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.